Dai Yuxiang, Ge Junbo
Shanghai Cardiovascular Institute and Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Thrombosis. 2012;2012:245037. doi: 10.1155/2012/245037. Epub 2011 Nov 24.
Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.
心血管疾病(CVD),主要是心脏病和中风,是发达国家男性和女性的主要死因。阿司匹林是心血管疾病中使用最广泛且经过测试的抗血小板药物,在各类人群的临床试验中,它被证明是治疗和预防心血管疾病抗血小板治疗的基石。在急性冠状动脉综合征、血栓性中风和川崎病中,急性使用阿司匹林可降低心血管事件的死亡率和复发率。作为二级预防,阿司匹林被认为对急性冠状动脉综合征、稳定型心绞痛、血管重建、中风、短暂性脑缺血发作(TIA)和心房颤动有效。阿司匹林也可用于未来心血管疾病风险高的患者进行一级预防,但必须考虑益处与副作用可能性之间的平衡。